Women researching hormonal health frequently encounter a confusing apparent contradiction: a doctor confirms that oestrogen levels are low, but symptoms — weight changes concentrated in the midsection, mood shifts, poor sleep, breast tenderness, irregular cycles — match what popular health sources describe as oestrogen dominance. Both descriptions seem to be true at the same time, and neither explains the other.

The resolution is not in the absolute level of either hormone. It is in the ratio between them. Oestrogen dominance is a condition of relative hormone balance, not absolute quantity. And when the full picture includes cortisol, chronic stress, and the endocannabinoid system's role across all three, the pattern becomes considerably more coherent.

The Ratio Mechanism — Why Absolute Levels Are Not the Whole Picture

Oestrogen and progesterone do not act independently. They act in relation to each other. The physiological effects of each hormone depend not only on its own concentration but on the balance between them — what is sometimes called the oestrogen-to-progesterone ratio, or E:P ratio.

In a normal menstrual cycle, the follicular phase is characterised by rising oestrogen with relatively low progesterone. After ovulation, progesterone rises sharply through the luteal phase, counterbalancing oestrogen's proliferative and stimulatory effects. The two hormones exist in deliberate tension. Their balance governs uterine lining development and shedding, mood stability through the cycle, breast tissue regulation, bone density maintenance, fluid retention, and a range of metabolic and neurological processes.

When this balance shifts — when the ratio tips toward oestrogen, regardless of the absolute level of either hormone — the clinical picture that follows is what researchers and clinicians have come to call oestrogen dominance. The critical point, and the one that resolves the apparent contradiction, is that the ratio can tip toward oestrogen in two very different ways.

The first is elevated oestrogen with normal progesterone — the classic picture most often described. The second is normal or low oestrogen with very low progesterone — in which oestrogen, though reduced, still dominates because its counterweight has fallen further. This second pattern is common in perimenopause, in women under sustained chronic stress, and in women whose ovulatory function has been disrupted.

A woman in perimenopause whose oestrogen has declined by 40 percent but whose progesterone has declined by 70 percent is oestrogen dominant by any ratio measure — despite having objectively low oestrogen levels. The symptoms she experiences are not paradoxical. They are the predictable consequence of an imbalanced ratio.

Progesterone's Vulnerability to Stress

Of the two primary sex hormones, progesterone is considerably more vulnerable to disruption by the stress response than oestrogen. This is not incidental — it reflects the body's prioritisation logic under threat. When survival demands immediate metabolic and neurological resources, the reproductive system is deprioritised. The mechanism through which this happens is direct and well-documented.

Progesterone in the luteal phase is produced primarily by the corpus luteum — the temporary endocrine structure that forms in the ovary after ovulation. The corpus luteum is sensitive to luteinising hormone (LH), which drives progesterone synthesis, and it is also sensitive to cortisol, which suppresses it. Under conditions of sustained elevated cortisol, LH pulsatility from the hypothalamus is reduced, and the corpus luteum's ability to maintain progesterone output is directly impaired.

There is a second pathway. Pregnenolone — the steroid precursor from which both progesterone and cortisol are synthesised — is diverted preferentially toward cortisol production under stress. Some researchers have described this as the "pregnenolone steal," though that framing overstates the linear competition between pathways. What is established is that sustained demand for cortisol production alters the steroidogenic environment in ways that reduce available progesterone.

The practical consequence of both mechanisms is that chronically stressed women often show shortened luteal phases, reduced mid-luteal progesterone concentrations, and in more severe cases, anovulatory cycles — cycles in which ovulation does not occur and the corpus luteum is never formed. Without ovulation, there is no corpus luteum, and without the corpus luteum, there is no significant progesterone production for that cycle.

The relationship between stress and oestrogen dominance runs directly through progesterone. Elevated cortisol does not raise oestrogen. It reduces the progesterone that counterbalances it.

The Xenoestrogen Dimension

A third pathway to oestrogen dominance — distinct from elevated endogenous oestrogen or depleted progesterone — involves xenoestrogens: synthetic chemical compounds that bind to oestrogen receptors or mimic oestrogen's biological effects. These include a range of widely distributed compounds in plastics, pesticides, personal care products, and industrial chemicals. Bisphenol A (BPA), certain phthalates, and organochlorine pesticides are the most studied.

Xenoestrogens do not raise measured serum oestradiol. They are not detected by standard hormone panels. But they occupy oestrogen receptors — in some tissues more potently than endogenous oestradiol — producing oestrogenic effects without being measured as oestrogen. A woman with objectively normal or low oestradiol levels can be experiencing significantly elevated total oestrogenic activity if her receptor occupancy by xenoestrogens is substantial.

This dimension connects oestrogen dominance to the broader environmental endocrine disruption research covered in the planned archive articles on endocrine disruptors and environmental hormone exposure. It also adds a practical dimension to the oestrogen dominance picture: in some cases, the pathway to resolution involves reducing exposure, not only modulating endogenous hormone production.

The endocannabinoid system's relationship to xenoestrogen exposure is an active research area. CB1 receptor expression appears to be sensitive to endocrine-disrupting chemical exposure, and some studies have examined whether ECS dysregulation contributes to the downstream hormonal effects of xenoestrogen burden. This research is early and not yet at a tier that supports specific mechanistic claims.

Where the ECS Intersects This Picture

The endocannabinoid system does not sit outside the oestrogen dominance pattern. It sits inside it, at multiple points simultaneously.

The first intersection is with oestrogen itself. As covered in detail in the ECS and Oestrogen article in this archive, oestrogen upregulates anandamide synthesis through NAPE-PLD and simultaneously downregulates FAAH — the enzyme that degrades anandamide. The net effect is elevated endocannabinoid tone in high-oestrogen states. In relative oestrogen dominance — where oestrogen's influence exceeds progesterone's regardless of absolute levels — this mechanism remains active. The ratio matters for symptom experience, but the ECS responds to the oestrogen signal, not the ratio.

The second intersection is with progesterone. Progesterone has approximately the opposite relationship to the ECS from oestrogen. Where oestrogen elevates endocannabinoid tone, progesterone suppresses it — primarily through FAAH upregulation, which accelerates anandamide degradation. In states of progesterone depletion, one of the resulting effects is a reduction in FAAH-mediated downregulation, which paradoxically could maintain some degree of anandamide availability. But this is not a protective compensation — it is an artefact of a depleted system, not a supported one.

The third intersection is with cortisol. Cortisol suppresses endocannabinoid tone through multiple pathways. CB1 receptor expression is reduced under sustained glucocorticoid exposure. Anandamide availability is reduced under chronic stress conditions. The same cortisol elevation that depletes progesterone and worsens the E:P ratio also directly suppresses ECS function. The two effects compound each other.

A woman experiencing oestrogen dominance driven by stress-mediated progesterone depletion is therefore experiencing reduced ECS tone through two converging pathways: reduced progesterone support for GABA-mediated stress buffering, and direct cortisol-driven ECS suppression. These are not independent processes running in parallel. They are mechanistically linked.

Progesterone, Allopregnanolone, and the GABA Connection

One of progesterone's most significant neurological functions is not direct. It operates through a metabolite: allopregnanolone, a neurosteroid produced from progesterone in the brain and periphery. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors — it enhances the sensitivity of the primary inhibitory neurotransmitter system in the brain.

In practical terms, adequate progesterone supports allopregnanolone production, and allopregnanolone supports the GABAergic calm that underlies anxiety regulation, stress recovery, and sleep architecture. Progesterone depletion — whether from chronic stress, perimenopause, or other causes — reduces allopregnanolone availability and with it the GABA-A receptor modulation that buffers against anxiety and supports restorative sleep.

The ECS and the GABAergic system intersect at multiple points. CB1 receptor activation in inhibitory interneurons modulates GABA release. The two systems are not independent parallel calming mechanisms — they interact. Disruption in one affects the other. When both progesterone-allopregnanolone-GABA support and direct ECS tone are reduced simultaneously, as they are under sustained stress in the oestrogen dominance context, the effects on mood, sleep, and stress resilience compound.

This is the mechanistic basis for why the oestrogen dominance picture — particularly the stress-driven variant — tends to present with sleep disruption, anxiety, and mood instability alongside the more commonly recognised hormonal symptoms. The neurological substrate is being undermined from multiple directions at once.

CBG and CBD in This Context

Neither CBG nor CBD corrects hormonal imbalances, raises progesterone, or reduces oestrogen. Those are not documented effects of either cannabinoid in human research, and any framing that implies them would be inaccurate. What the research documents is mechanistic intersection — points where CBG and CBD's confirmed actions cross the biological pathways involved in oestrogen dominance — and those intersections are worth understanding precisely.

CBG's most relevant mechanisms in this context are its HPA axis interactions. The documented mechanisms — alpha-2 adrenoceptor agonism reducing noradrenaline release, partial CB1 agonism in the limbic system, and the cortisol-modulating effects shown in the first controlled human CBG trial — all operate within the stress response system whose dysregulation is the primary driver of stress-mediated progesterone depletion. CBG does not prevent cortisol from suppressing progesterone. But it acts on the HPA axis components that determine how much cortisol is produced and how the system recovers.

CBD's most relevant mechanism is FAAH inhibition. In the oestrogen dominance context, this is meaningful in two related ways. First, FAAH inhibition increases anandamide availability — and anandamide, as an endogenous CB1 agonist, contributes to HPA axis termination through the same limbic pathways that CBG engages. Second, the progesterone-FAAH relationship runs in both directions: progesterone upregulates FAAH, and FAAH inhibition by CBD partially counteracts progesterone's suppressant effect on endocannabinoid tone. In progesterone-depleted states, where FAAH activity may be lower but the broader ECS support system is diminished, CBD's FAAH inhibition operates in a different biochemical environment than it does in normal hormonal conditions.

CBG's PPAR-γ activation is also potentially relevant. PPAR-γ is involved in adipose tissue metabolism, and visceral fat accumulation — a recognised feature of oestrogen dominance and chronic cortisol elevation — is associated with elevated aromatase activity in adipose tissue. Aromatase converts androgens to oestrogen, creating a secondary source of oestrogen production independent of ovarian function. Whether CBG's PPAR-γ activity meaningfully intersects with this pathway is not established in research. It is a mechanistic hypothesis worth noting and worth watching as the research develops.

The Honest Evidence Summary

Oestrogen dominance as a clinical concept is well-established and the ratio mechanism is not contested. The stress-progesterone connection through corpus luteum cortisol sensitivity and HPA-HPG crosstalk is documented in preclinical and clinical literature. The ECS intersections described in this article — oestrogen-FAAH, progesterone-FAAH, cortisol-CB1, allopregnanolone-GABA-ECS — are established in mechanistic and preclinical research.

What is not established: no human trial has examined CBG or CBD specifically in oestrogen dominance contexts. No research has demonstrated that either cannabinoid corrects the E:P ratio, raises progesterone, or measurably reduces oestrogenic activity. The connections described here are mechanistic plausibility — the documented actions of these compounds intersect documented pathways. That intersection is real and worth understanding. It is not evidence of clinical efficacy for a specific hormonal outcome.

Women with suspected oestrogen dominance, significant hormonal symptoms, or perimenopausal changes should have these evaluated by a clinician with access to appropriate hormonal testing. The E:P ratio cannot be assessed without both oestrogen and progesterone measurements in the appropriate cycle context.